As the acquired and intrinsic resistance mechanisms of endocrine therapy drug and CDK4/6 inhibitors is gradually revealed, there is a need to develop novel endocrine drugs with higher efficacy and fewer side effects for breast cancer patients (107). Here, CDK4 is linked to breast cancer.